Sector News

India’s Sun Pharma open to large acquisitions post Ranbaxy deal

March 25, 2015
Life sciences
(Reuters) – Sun Pharmaceutical Industries Ltd, India’s largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.
 
The company will look to invest more than $300 million in research and development and is not considering any job cuts post the close of the deal, Managing Director Dilip Shanghvi told reporters in Mumbai.
 
Shanghvi, who founded Sun Pharma and is one of the country’s richest men, added that the company’s “most important focus” would be to win confidence of regulators.
 
Sun Pharma’s third-quarter profit was hit by costs incurred to address observations raised by the U.S. Food and Drug Administration after an inspection of the company’s manufacturing plant in western India.
 
“Every investment I have made outside of Sun is financial, I have no interest in running those businesses,” said Shanghvi, who invested $290 million for a 23 percent stake in wind turbine maker Suzlon Energy Ltd last month.
 
The company’s shares were up 1 percent in afternoon trading on Wednesday, while the benchmark index was down 0.16 percent. (Reporting by Zeba Siddiqui in Mumbai; Writing by Aman Shah; Editing by Anand Basu)
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend